Movement Disorders

Over a 12-month stretch, patients with spinocerebellar ataxia type 2 treated with riluzole showed significant worsening in Composite Cerebellar Functional Severity Score.

Next steps for medical cannabis will need to include how cannabinoids affect the brain, according to the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel.

A study from the International Parkinson and Movement Disorder Society Virtual Congress suggest that despite protocol adherence, average costs are moderately high and vary significantly.

The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel discussed future use of medical cannabis and concerns for psychiatric adverse effects.

The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel outlined the small, retrospective study, shedding light on its findings.

Here's what is coming soon to NeurologyLive.

The FIGHT-PD study is expected to complete and read out interim results before the end of 2021. It aims to assess the exercise program’s safety, tolerability, and efficacy in Parkinson disease.

The professor of neurology at Weill Cornell Medical School commented on the available treatments for Parkinson disease, as well as ongoing therapeutic development.

Patients previously randomized to omaveloxolone in the core study period continued to show no worsening on modified Friedrich Ataxia Rating Scale relative to their original baseline after nearly 2.5 years of treatment.

Patients who underwent deep brain stimulation procedures that were managed postoperatively in the home reported significantly fewer clinic visits with similar MDS-UPDRS scores to standard of care.

Investigators noted the psychiatric adverse effects of treatment with medical cannabis, requiring patient monitoring after initiation.

Despite not meeting the primary end point, those in the early-start group showed reduced change from baseline in MDS-UPDRS-III scores compared with the delayed-start group at both weeks 52 and 104.

Data from the PRIME-NL study showed stressors resulting from the pandemic impacted depression, anxiety, and quality of life.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 17, 2021.

Improvements in mean total amount of time and percentage of participants that were awake suggested limited effect with opicapone (Ogentys; Neurocrine Bio).

The director of the Movements Disorders Clinic at Houston Methodist Neurological Institute discussed data presented at the International Parkinson and Movement Disorders Society Virtual Congress 2021.

Patients with Parkinson disease in both the 24-hour and 16-hour ND0612 dosing regimen groups had ON-state UPDRS-motor scores and UPDRS-ADL scores improve over the 12-month period.

The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.

Data from MDS 2021 suggest that a 6-week brisk walking program can improve MDS-UPDRS nonmotor scores significantly compared to standard stretching interventions.

Torticollis was the most common predominant cervical dystonia presentation subtype at injection 1, followed by laterocollis.

When comparing only the lowest and highest HbA1c groups with each other, unadjusted and adjusted regression analysis indicated faster motor progression in the highest group.

The division chief of vascular neurology at the University of Utah discussed the misperceptions surrounding the field of neurology, as well as the importance of increasing fellowship training.

The SELECT-HD trial (NCT05032196) is expected to enroll approximately 36 patients with a confirmed diagnosis of early-stage Huntington disease and carry the SNP3 allele in association with their CAG expression.

The division chief of vascular neurology at the University of Utah discussed the driving force behind the national shortage of neurologists and its effect on patient care.

Here's what is coming soon to NeurologyLive.

Jennifer Majersik, MD, MS, commented on how the AAN, as well as current neurologists and specialists, can help generate interest in the field of neurology to meet patient needs.

Jennifer Majersik, MD, MS, division chief of vascular neurology at the University of Utah, discussed contributing factors to the neurologist shortage, as well as ongoing efforts to increase interest in the field.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 10, 2021.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.